SCHEMBL1884548

SCHEMBL1884548

[CH2]CC(NC(=O)OCOC(=O)C(C)(C)C)c1ccc(Cl)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.37
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
CNR1 P21554 4/20 0.37
CNR2 P34972 3/20 0.37
NPC1 O15118 2/20 0.36
CYP1A2 P05177 2/20 0.36
KMT2A Q03164 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
UTS2R Q9UKP6 5/20 0.35
ELANE P08246 1/20 0.35
CYP26A1 O43174 1/20 0.35
ABCB11 O95342 1/20 0.35
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
HTR2A P28223 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2231120 0.85 UTS2R (0.40) KMT2AUTS2RCYP26A1
SCHEMBL1884875 0.85 SMN1; SMN2 (0.39) SMN1; SMN2LMNAHTTCNR1CNR2
SCHEMBL637463 0.83 ELANE (0.39) UTS2RELANE
SCHEMBL1884159 0.82 SMN1; SMN2 (0.37) SMN1; SMN2LMNAHTTCNR2CYP1A2
SCHEMBL1886107 0.81 CNR1 (0.38) SMN1; SMN2LMNAHTTCNR1CNR2
SCHEMBL1883473 0.81 UTS2R (0.36) UTS2R
SCHEMBL391128 0.80 PPARG (0.46) LMNACNR1CNR2UTS2RTSHR
SCHEMBL20544831 0.80 PPARG (0.46) LMNACNR1CNR2UTS2RTSHR
SCHEMBL915625 0.78 TP53 (0.45) LMNAHTTKMT2AUTS2RPPARA
SCHEMBL1884547 0.78 MAPT (0.36) SMN1; SMN2LMNANPC1CYP1A2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS SMN1; SMN2 900/4885LMNA 3723/4885HTT 1465/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS SMN1; SMN2 900/4885LMNA 3723/4885HTT 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.